Skip to search formSkip to main contentSkip to account menu

buparlisib

An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

NVP-BKM120

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
[This corrects the article on p. 23 in vol. 10, PMID: 29430197.]. 
2018
2018
Abstract PD5-12: Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative…
Background: BELLE-2 (NCT01610284) met its primary endpoint of a statistically significant improvement in progression-free… 
2017
2017
Head and neck cancer: Buparlisib is an effective second-line treatment
2016
2016
Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally…
Background: Growing evidence suggests that concomitant inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian… 
2016
2016
Abstract P3-07-41: Genomic alterations indicative of a luminal A subtype associate with clinical benefit to buparlisib and letrozole in endocrine-resistant ER+/HER2– metastatic breast cancer
Background: Activation of the phosphoinositide-3-kinase (PI3K) pathway has been associated with resistance to endocrine therapy… 
2015
2015
PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the…
2015
2015
A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.
TPS633 Background: The PI3K/AKT/mTOR pathway is the most frequently activated signaling pathway in breast cancer (BC). PIK3CA… 
2015
2015
Buparlisib Benefits Women With PIK3CA Mutations in Circulating Tumor DNA
Women with advanced endocrine-resistant breast cancer who had PIK3CA mutations in their circulating tumor DNA had an almost 4… 
2013
2013
Abstract OT2-6-07: Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K…
Background: Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) is the most frequently activated… 
2013
2013
Buparlisib (NVP-BKM-120)